Clinical Research Directory
Browse clinical research sites, groups, and studies.
Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
Sponsor: Han weidong
Summary
The purpose of this study is to assess the feasibility, safety, and efficacy of anti-PD-1 antibody alone or in combination with low-dose decitabine in patients with relapsed or refractory malignancies, including Non-Hodgkin'lymphoma, Hodgkin'lymphoma, gastrointestinal cancers, hepatocellular carcinoma, breast cancer, ovarian cancer or lung cancer or renal-cell cancer or pancreatic cancer or bile duct cancer.
Official title: Anti-PD-1 Antibody Alone or in Combination With Low-dose Decitabine and/or Chemotherapy in Relapsed or Refractory Malignancies: an Open-label Phase I/II Trial
Key Details
Gender
All
Age Range
12 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
250
Start Date
2016-05
Completion Date
2026-05
Last Updated
2026-01-22
Healthy Volunteers
No
Conditions
Interventions
Anti-PD-1 antibody
Anti-PD-1 antibody will be given at 1-3mg/kg on day8 by IV every three weeks
Decitabine
Decitabine will be given at 10mg/d on day 1to 5 by IV every three weeks
Chemotherapy
Chemotherapy be given depends on the cancer type and treatment regimen before enrollment.
Locations (1)
Biotherapeutic Department of Chinese PLA General Hospital
Beijing, Beijing Municipality, China